Navigation Links
SFJ Pharma Ltd. II, Announces Agreement With Pfizer to Develop Axitinib for Adjuvant Treatment of Renal Cell Carcinoma
Date:1/9/2012

SAN FRANCISCO, January 9, 2012 /PRNewswire/ --

SFJ Pharma Ltd. II (President & CEO: Robert F. DeBenedetto, "SFJ") announced today that it has entered into a collaborative development agreement with Pfizer Inc. to conduct a Phase 3 clinical trial in Asia of Pfizer's investigational agent axitinib for the adjuvant treatment of patients at high risk of recurrent renal cell carcinoma (RCC) following nephrectomy.

Axitinib is an oral and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2 and 3, receptors that can influence tumor growth, vascular angiogenesis and progression of cancer. It has been widely studied in a broad clinical development program, evaluating its efficacy and safety in more than 2,500 patients across several tumor types. Axitinib is currently under review by the U.S. Food and Drug Administration, the European Medicines Agency, the Japanese Ministry of Health, Labour and Welfare, and several other regulatory agencies around the world as a treatment for advanced RCC.

Under the terms of the agreement, SFJ will provide the funding and clinical development supervision to generate the clinical data necessary to submit axitinib for review by regulatory authorities for the adjuvant treatment of patients at high risk of recurrent RCC following nephrectomy. SFJ will be eligible to receive milestone payments under the agreement.

In addition, if approved, Pfizer intends to commercialize axitinib for this indication and SFJ will receive earn- out payments under the agreement. "We appreciate the opportunity to collaborate with Pfizer for one of their most promising oncology compounds," said Robert DeBenedetto. "We believe SFJ's new co-development model will benefit patients by allowing Pharma companies like Pfizer to develop even more compounds simultaneously."

"We recognize the need to look for new and innovative ways to advance our clinical programs and bring our many promising compounds to pat
'/>"/>

SOURCE SFJ Pharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Reata Pharmaceuticals to Present at 30th Annual J.P. Morgan Healthcare Conference
2. HealthCare Institute of New Jersey Releases 2011 Biopharmaceutical and Medical Technology Economic Impact Data
3. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
4. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
5. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
6. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
9. PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
10. The respective roles of the public and private sectors in pharmaceutical innovation
11. PDL BioPharma Completes Regular Quarterly Dividend Payment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... cell fragments whose job it is to stop bleeding, ... But they can "feel" the physical environment around them, ... Platelets respond to surfaces with greater stiffness by increasing ... other platelets and other components of the clotting system, ... give them credit for, in that they are able ...
(Date:9/22/2014)... a highly sensitive chemical sensor based on the crystalline ... properties that the researchers were able to exploit to ... , The study is available online in advance of ... Khojin, asst professor of mechanical and industrial engineering in ... Kumar, post doc where they are doing research in ...
(Date:9/22/2014)... NY (PRWEB) September 22, 2014 Topical ... helping those in pain end their suffering, restoring hope ... healthcare model. This is only possible because of the ... and healing cream technology a reality. , The ... Rhinebeck, NY, by Lou Paradise (president, chief of research, ...
(Date:9/22/2014)... 22, 2014 Invisible Sentinel Inc., ... the food and beverage industries, announced today that ... under a non-exclusive agreement by Enartis, a global ... Enartis, an Esseco Group company headquartered in Trecate, ... California and other global markets for their own ...
Breaking Biology Technology:Platelets modulate clotting behavior by 'feeling' their surroundings 2Graphene imperfections key to creating hypersensitive 'electronic nose' 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 3Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 4Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 5Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 6Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 2Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 3
... ... and Genedata Expressionist® at Evonik for Industrial Biotechnology R&D Processes , ... Basel, Switzerland (PRWEB) ... industrial biotechnology R&D, today announced an extended partnership with Evonik, a leading life ...
... ... ... , ... , , , ...
... in the development of practical phonon lasers, which emit sound ... The development should lead to new, high-resolution imaging devices and ... countless, ubiquitous devices, a phonon laser is likely to be ... Two separate research groups, one located in the US and ...
Cached Biology Technology:Evonik Extends Long-term Research & Development Partnership with Genedata 2Evonik Extends Long-term Research & Development Partnership with Genedata 3Evonik Extends Long-term Research & Development Partnership with Genedata 4Sanaria Inc. Receives Multi-Year U.S. NIH Phase II Small Business Innovation Research Grant to Develop a Genetically Attenuated Whole Parasite Malaria Vaccine 2Sanaria Inc. Receives Multi-Year U.S. NIH Phase II Small Business Innovation Research Grant to Develop a Genetically Attenuated Whole Parasite Malaria Vaccine 3Sanaria Inc. Receives Multi-Year U.S. NIH Phase II Small Business Innovation Research Grant to Develop a Genetically Attenuated Whole Parasite Malaria Vaccine 4Quantum leap for phonon lasers 2
(Date:9/21/2014)... what was previously thought, newborn immune T cells may ... bacteria, according to a new study led by King,s ... to that of adults, babies may still be able ... published in the journal Nature Medicine . , ... types of immune cells, including neutrophils which play an ...
(Date:9/19/2014)... by researchers from several Harvard University labs in ... and aspiring researchers with the intellectual raw materials ... from soft, flexible materials. , With the advent ... advances in manufacturing technology, soft robotics is emerging ... from conventional rigid robot design, but working with ...
(Date:9/19/2014)... are a species which over thousands of years has adapted ... a substance that makes the cold dangerous for you. , ... albidus , and the cold provoking substance, called nonylphenol, comes ... Nonylphenol is suspected of being a endocrine disruptor, but when ... the worm,s ability to protect the cells in its body ...
Breaking Biology News(10 mins):Immune system of newborn babies is stronger than previously thought 2Soft robotics 'toolkit' features everything a robot-maker needs 2Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3
... average life expectancy and decreases recurrences of tumors in ... according to researchers at Rhode Island Hospital. , In ... the median survival rate at three years increased from ... thermal ablation was followed by radiation for treatment of ...
... a study comparing wild rodents with their laboratory counterparts, ... that may help to explain why people in industrialized ... allergy and autoimmune diseases than do people in less ... or considered less critical. , The prevailing hypothesis concerning ...
... week's Analytical Chemistry, scientists at Indiana University Bloomington ... to follow the weakest of scents. Even when ... cells still found their mark. , A video ... a chemical gradient) can be downloaded at ...
Cached Biology News:Combined treatment extends life expectancy for lung cancer patients 2Combined treatment extends life expectancy for lung cancer patients 3Wild vs. lab rodent comparison supports hygiene hypothesis 2Wild vs. lab rodent comparison supports hygiene hypothesis 3Wild vs. lab rodent comparison supports hygiene hypothesis 4Even when faint, ovary scent draws sperm cells 2
Proliferin (C-14)...
Porcine Pulmonary Artery Endothelial Cells (PPAEC) (>500,000 cells)...
... Ascent is a dedicated fluorometer ... all kinds of assays in ... for clinical applications. Cell biology, ... all important application areas. Robot-friendly ...
... Thermo Savant's latest SpeedVac Concentrator, the ... and adds a new modern twist., The ... controller and gauge for optimizing runs; preventing ... to be stopped at the end-users preset ...
Biology Products: